GSK5733584

Phase 3Small molecule

GSK

GSK5733584 is one of 46 small molecule programs targeting Neoplasms, Endometrial. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neoplasms, EndometrialNot yet recruiting

Solid TumorRecruiting

Tumours, GynecologicalRecruiting

Neoplasms, EndometrialPhase 3

Not yet recruiting

Solid TumorPhase 1

Recruiting

Tumours, GynecologicalPreclinical

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

GSK5733584

GSK

Phase 3

1 2

Fludara

Sanofi

Preclinical

1 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 5

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 8

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 9

Tulmimetostat

Novartis

Preclinical

1 10

Carboplatin AUC-5

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Tumours, Gynecological

NCT06796907

Q2 2029

Phase 3Recruiting

Neoplasms, Endometrial

NCT07286331

Q4 2029

Phase 3Recruiting

Ovarian Neoplasms

NCT07286266

Phase 1Recruiting

Solid Tumor

NCT06431594

Q3 2031

Phase 3Not yet recruiting

Neoplasms, Endometrial

NCT07684599

Clinical

Trials by Indication[1]

Neoplasms, Endometrial2 trials

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan in Combination With Immune Checkpoint Inhibition for Maintenance Treatment of Participants With Mismatch Repair Proficient (MMRp) Endometrial Cancer

Not yet recruiting· GSK logo

GSK·Phase 3·NCT07684599·610 enrolled

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy

Recruiting· GSK logo

GSK·Phase 3·NCT07286331·600 enrolled

Ovarian Neoplasms1 trial

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer

Recruiting· GSK logo

GSK·Phase 3·NCT07286266·450 enrolled

Tumours, Gynecological1 trial

A Phase 1/2 Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

Recruiting· GSK logo

GSK·Preclinical·NCT06796907·305 enrolled

Solid Tumor1 trial

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors

Recruiting· GSK logo

GSK·Phase 1·NCT06431594·675 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GSK5733584. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK5733584 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK5733584. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

GSK5733584

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Q4 2029

Q3 2031

Trials by Indication[1]

Neoplasms, Endometrial2 trials

Ovarian Neoplasms1 trial

Tumours, Gynecological1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News